Brief: Seres Therapeutics Announces US FDA Fast Track Designation For SER-155
09/01/2024 13:32
Jan 9 (Reuters) - Seres Therapeutics Inc MCRB.O :
* SERES THERAPEUTICS ANNOUNCES VOWST™ COMMERCIAL LAUNCH
UPDATE AND
US FDA FAST TRACK DESIGNATION FOR SER-155
* SERES THERAPEUTICS INC - VOWST PRELIMINARY NET SALES OF
APPROXIMATELY $10.4 MILLION (UNAUDITED) FOR Q4 OF 2023
* SERES THERAPEUTICS INC - SER-155 PHASE 1B
PLACEBO-CONTROLLED
COHORT 2 DATA READOUT ANTICIPATED IN Q3 OF 2024
Source text for Eikon: ID:nBw9QwHMFa
Further company coverage: MCRB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seres Therapeutics
See all newsChinese automakers make tech-led pitch for Europe's premium car market
Brief: Seres Therapeutics - May Offer Up To $300 Million Of Securities
Seres Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Seres Therapeutics Q2 net income turns positive on VOWST sale gain
Brief: Seres Therapeutics Q2 EPS USD 0.47